PersonalisPSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 225
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
510% more capital invested
Capital invested by funds: $25.8M [Q2] → $158M (+$132M) [Q3]
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
20% more funds holding
Funds holding: 69 [Q2] → 83 (+14) [Q3]
12.59% more ownership
Funds ownership: 42.52% [Q2] → 55.11% (+12.59%) [Q3]
39% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 28
60% less call options, than puts
Call options by funds: $183K | Put options by funds: $459K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 34% 1-year accuracy 66 / 193 met price target | 63%upside $8 | Buy Maintained | 27 Jan 2025 |
Lake Street Thomas Flaten 17% 1-year accuracy 2 / 12 met price target | 83%upside $9 | Buy Maintained | 8 Jan 2025 |
Needham Mike Matson 60% 1-year accuracy 74 / 124 met price target | 47%upside $7.25 | Buy Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 3 articles about PSNL published over the past 30 days









